Tumor selective uptake of drug-nanodiamond complexes improves therapeutic outcome in pancreatic cancer.


Journal

Nanomedicine : nanotechnology, biology, and medicine
ISSN: 1549-9642
Titre abrégé: Nanomedicine
Pays: United States
ID NLM: 101233142

Informations de publication

Date de publication:
06 2019
Historique:
received: 25 07 2018
revised: 25 11 2018
accepted: 05 02 2019
pubmed: 9 3 2019
medline: 4 12 2019
entrez: 9 3 2019
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths and novel treatment approaches are urgently needed. Here we show that poly(ethylene glycol)-functionalized nanodiamonds loaded with doxorubicin (ND-PEG-DOX) afforded a considerable improvement over free drug in an orthotopic pancreatic xenograft model. ND-PEG-DOX complexes were also superior to free DOX in 3-dimensional (3D) tumor spheroids of PDAC. ND-PEG showed no cytotoxicity towards macrophages, and histopathological analysis showed no abnormalities of major organs upon in vivo administration of ND-PEG-DOX. These results provide evidence that ND-mediated drug delivery may serve as a means of improving the therapeutic outcome in PDAC.

Identifiants

pubmed: 30849547
pii: S1549-9634(19)30051-6
doi: 10.1016/j.nano.2019.02.020
pmc: PMC6588439
mid: NIHMS1523284
pii:
doi:

Substances chimiques

Nanodiamonds 0
Polyethylene Glycols 3WJQ0SDW1A
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112-121

Subventions

Organisme : NCI NIH HHS
ID : R01 CA078383
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA150190
Pays : United States
Organisme : NCI NIH HHS
ID : R29 CA078383
Pays : United States

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Références

ACS Nano. 2014 Dec 23;8(12):12151-66
pubmed: 25437772
Biomaterials. 2017 Mar;121:28-40
pubmed: 28063981
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Nanomedicine. 2015 Oct;11(7):1689-94
pubmed: 26051651
Cancers (Basel). 2018 Jan 29;10(2):
pubmed: 29382159
Nanotechnology. 2014 Oct 24;25(42):425103
pubmed: 25277401
Adv Mater. 2016 Apr 13;28(14):2699-708
pubmed: 26833992
Adv Drug Deliv Rev. 2013 Dec;65(15):2087-97
pubmed: 23751779
Expert Rev Anticancer Ther. 2014 Oct;14(10):1115-25
pubmed: 25204327
Nat Nanotechnol. 2011 Dec 18;7(1):11-23
pubmed: 22179567
Nanomedicine. 2014 Oct;10(7):1421-31
pubmed: 24491397
Biomaterials. 2012 Nov;33(31):7794-802
pubmed: 22863379
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jan;11(1):e1531
pubmed: 29923692
Adv Drug Deliv Rev. 2010 Mar 8;62(3):346-61
pubmed: 19914317
ACS Nano. 2018 Jan 23;12(1):24-43
pubmed: 29257865
Nat Rev Clin Oncol. 2016 Dec;13(12):750-765
pubmed: 27531700
Sci Transl Med. 2011 Mar 9;3(73):73ra21
pubmed: 21389265
J Natl Cancer Inst. 2015 Jan 31;107(2):
pubmed: 25638248
Sci Rep. 2017 Oct 10;7(1):12877
pubmed: 29018205
Nat Rev Cancer. 2017 Nov;17(11):659-675
pubmed: 29026204
Exp Mol Med. 2017 Dec 1;49(12):e406
pubmed: 29611542
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
ACS Nano. 2016 Jan 26;10(1):1170-81
pubmed: 26643115
Nat Commun. 2018 Apr 12;9(1):1410
pubmed: 29650952
Sci Adv. 2015 Aug 21;1(7):e1500439
pubmed: 26601235
J Mater Chem B. 2016 Aug 7;4(29):5046-5058
pubmed: 32264031
Nanomedicine. 2016 Feb;12(2):333-51
pubmed: 26707820
Nat Commun. 2018 Oct 31;9(1):4548
pubmed: 30382085
Nanoscale. 2016 Feb 28;8(8):4452-7
pubmed: 26847879
Cancers (Basel). 2014 Oct 21;6(4):2137-54
pubmed: 25337831
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Adv Drug Deliv Rev. 2014 Dec 15;79-80:95-106
pubmed: 24996135
ACS Nano. 2016 Aug 23;10(8):7385-400
pubmed: 27439019
J Control Release. 2012 Jul 20;161(2):403-8
pubmed: 22306428
Environ Sci Process Impacts. 2014 Mar;16(3):518-23
pubmed: 24352711
Ann Surg Oncol. 2016 Feb;23 Suppl 2:S197-205
pubmed: 25749932
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473

Auteurs

Vijay S Madamsetty (VS)

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, United States.

Anil Sharma (A)

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, United States.

Maria Toma (M)

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Stefanie Samaniego (S)

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Audrey Gallud (A)

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Enfeng Wang (E)

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, United States.

Krishnendu Pal (K)

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, United States.

Debabrata Mukhopadhyay (D)

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Jacksonville, FL, United States; Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Jacksonville, FL, United States. Electronic address: mukhopadhyay.debabrata@mayo.edu.

Bengt Fadeel (B)

Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: bengt.fadeel@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH